1 ACE inhibitors, AT1 receptor blockers and COVID-19 : clinical epidemiology evidences for a 2 continuation of treatments. The ACER-COVID study

3

4

5 Luc Dauchet^{1,2}, MD, PhD, Marc Lambert^{2,3}, MD, PhD, Victoria Gauthier², PharmD, Julien Poissy⁴, MD
6 PhD, Karine Faure^{5,6}, MD, PhD, Alain Facon⁷, MD, Cécile Yelnik³, MD, Sophie Panaget⁵, MD, Thierry
7 Plagnieux⁸, MD, Florent Verfaillie⁸, MD, Daniel Mathieu⁴, MD, PhD, Patrick Goldstein⁷, MD, Aline
8 Meirhaeghe²; PhD and Philippe Amouyel^{1,2}, MD, PhD, on behalf of the Lille COVID-19 study group.

9

10 1. CHU Lille, Department of Public Health, Epidemiology, Medical Economy and Prevention, F-59000,
11 Lille, France

12 2. Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk factors and molecular
13 determinants of aging-related diseases, F-59000, Lille, France

14 3. CHU Lille, Internal Medicine Department, F-59000, Lille, France

15 4. CHU Lille, Department of Intensive Care, F-59000, Lille, France

16 5. CHU Lille, Department of Infectious Diseases, F-59000, Lille, France

17 6. Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre
18 d'Infection et d'Immunité de Lille, F-59000, Lille, France

19 7. CHU Lille. SAMU 59 and Emergency Department, F-59000, Lille, France

20 8. DRSM Hauts de France, F-59009, Villeneuve d'Ascq, France.

21

22 This clinical study took place at the University Hospital of Lille (Centre Hospitalier et Universitaire de
23 Lille, CHU Lille)

24

25 **Word count = 4,758**

26

1 **Corresponding author**

2 Prof. Philippe AMOUYEL, MD, PhD

3 Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk factors and molecular

4 determinants of aging-related diseases,

5 Institut Pasteur de Lille

6 1 rue Pr. Calmette

7 F-59000, Lille

8 France

9 Email : philippe.amouyel@pasteur-lille.fr

10 ORCID : 0000-0001-9088-234X

11 Phone : +33 6 86 43 23 34

12 Fax : +33 3 20 87 78 94

1 **Abstract**

2 **Aims:** The question of interactions between the renin angiotensin aldosterone system drugs and the
3 incidence and prognosis of COVID-19 infection has been raised by the medical community. We
4 hypothesised that if patients treated with ACE inhibitors (ACEI) or AT1 receptor blockers (ARB) were
5 more prone to SARS-CoV2 infection and had a worse prognosis than untreated patients, the
6 prevalence of consumption of these drugs would be higher in patients with COVID-19 compared to
7 the general population.

8 **Methods and results:** We used a clinical epidemiology approach based on the estimation of
9 standardised prevalence ratio (SPR) of consumption of ACEI and ARB in four groups of patients
10 (including 187 COVID-19 positive) with increasing severity referred to the University hospital of Lille
11 and in three French reference samples (the exhaustive North population (n=1,569,968), a
12 representative sample of the French population (n=414,046), a random sample of Lille area
13 (n=1,584)).

14 The SPRs of ACEI and ARB did not differ as the severity of the COVID-19 patients increased, being
15 similar to the regular consumption of these drugs in the North of France population with the same
16 non-significant increase for both treatment (1.17 [0.83-1.67]). A statistically significant increase in
17 the SPR of ARB (1.56 [1.02-2.39]) was observed in intensive care unit patients only. After
18 stratification on obesity, this increase was limited to the high risk subgroup of obese patients.

19 **Conclusions:** Our results strongly support the recommendation that ACEI and ARB should be
20 continued in the population and in COVID-19 positive patients, reinforcing the position of several
21 scientific societies.

22
23 **Keywords :** ACE inhibitors, AT1 receptor blockers, COVID-19, clinical epidemiology.

24

1 Introduction

2 Since December 2019, the world is being facing the largest pandemic ever in this century. Although a
3 large number of the COVID-19 patients will be asymptomatic or develop a mild disease, 5% (1) will be
4 admitted to an ICU with an acute respiratory disease syndrome (ARDS) of highly severe prognostic. In
5 a retrospective study, men aged over 68 years with hypertension and other cardiovascular
6 comorbidities were more frequent among deceased patients (2). This observation of the association
7 of cardiovascular comorbidities with severe COVID19 prognostic has been constantly reported in
8 recent literature (3) where old age, cardiovascular disease, hypertension and diabetes were found to
9 be prognostic factors for the COVID-19 related death. These cardiovascular conditions strongly
10 benefit from the use of ACE inhibitors (ACEI) and AT1 receptor blockers (ARB) known to protect
11 against hypertension, myocardial fibrosis and hypertrophy (4). These treatments became a large area
12 of concern because of the key role of the Renin-Angiotensin-Aldosterone System (RAAS) in the
13 invasion of the SARS-CoV2 virus in human organisms (5). Indeed SARS-CoV2 is known to target the
14 host protein angiotensin converting enzyme 2 (ACE2) as a co-receptor to penetrate the intracellular
15 compartment of human alveolar epithelial cells and other tissues (6). The ACE2, a homolog of ACE
16 (7), is a key player of the beneficial effects of ACEI and ARB. ACE2 efficiently degrades angiotensin II,
17 a powerful vasoconstrictor, to Ang (1-7) with anti-inflammatory and anti-fibrotic actions.
18 Experimental studies tended to demonstrate that RAAS blockade enhances ACE2 properties by
19 stimulating ACE2 expression and/or activity, contributing to the expected benefits of these drugs (8).
20 These evidences prompted several questions: does this potential increase in the number of the
21 molecular gates of the virus induced by RAAS blockers favours its dissemination? Should RAAS
22 blockers be withdrawn in high risk patients with COVID-19 infection? Would this withdrawal modify
23 the severity of the infection? Different reviews (5,9, 10) have attempted to address these questions
24 compiling what is known in the field of basic research, experimental medicine and clinical trials, with
25 no definite conclusions, except that the lack of clear evidence should refrain physicians to withdraw
26 these treatments.

To address this key issue, we used clinical epidemiology to estimate the prevalence of consumption of ACEI and ARB in COVID patients compared to the general population. We assumed that if an increased susceptibility to SARS-COV2 infection and/or a deleterious effect occurred in patients using ACEI or ARB, the higher the consumption of these treatments, the higher the risk of infection and the severity of the clinical symptoms. We tested this hypothesis in four groups of patients of different severity referred to the University hospital of Lille (North of France) compared to three reference samples.

Methods

Study oversight

This mono-centric study took place at the University Hospital of Lille (Centre Hospitalier et Universitaire de Lille, CHU Lille) and designed by the investigators, trained physicians and epidemiologists, in the context of the French reference methodology MR004, as a descriptive noninvasive epidemiological studies in human. All the data collected were compliant with the GDPR of the University Hospital. The investigators were never in contact with the patients or their families. The study was approved by the institutional review board of the CHU Lille and declared to the Commission National Informatique et Liberté.

Patient samples and data collection

We collected clinical data from consecutive patients aged 35 years and over, referred to the CHU Lille for COVID-19 suspicion. We identified four groups of patients of different disease severity. In the first group, we registered all the individuals who called the national medical emergency number from 18th March to 5th April. Since the COVID-19 pandemic, each individual calling this number with any respiratory problems and/or cough and/or fever was immediately transferred to a dedicated COVID-19 call platform. A questionnaire was filled in to collect information on the current symptoms and the on-going anti-hypertensive treatments if any. The second group was composed of patients referred to an outpatient clinic dedicated to COVID-19 from 29th February to 23rd March and

1 benefited of genomic tests and clinical examination. The third group was composed of more severe
2 COVID-19 positive cases who needed hospitalisation in a specific ward from 26th February to 5th April.
3 The fourth group was composed of the most severe confirmed cases who needed to be hospitalised
4 in intensive care units (ICU) for oxygenotherapy or mechanical ventilation from 21st February to 3rd
5 April. Epidemiological, clinical and laboratory information, as well as risk factor levels and treatments
6 at entry were extracted from the electronic medical records.

7 **Reference populations and data collection**

8 We used three reference population samples to estimate the standardised prevalence ratio of anti-
9 hypertensive treatment consumption. The first one was composed of the 2019 medical records of
10 the exhaustive population of the North Department of France over 35 years of age (n=1,569,968)
11 where the CHU Lille is located. The relevant data were extracted from the national health insurance
12 information system (Système National d'Information Interrégimes de l'Assurance Maladie, SNIIRAM)
13 created in 1999 in order to determine and evaluate more precisely health care utilisation and health
14 care expenditure of beneficiaries. These nationwide data, based on almost 66 million inhabitants
15 comprises individual information on the socio-demographic and medical characteristics of
16 beneficiaries and all hospital care and office medicine reimbursements, coded according to various
17 systems (11). The second one was a 1/97th random sample of the SNIIRAM (Echantillon généraliste
18 des bénéficiaires, EGB), representative of France's national population of health insurance
19 beneficiaries over 35 years of age in 2017 (n=414,046). For these two reference samples we
20 extracted the numbers of beneficiaries that had either an ACEI, an ARB or any antihypertensive drug
21 estimated by the presence of three or more reimbursements recorded of these products during the
22 year (2019 for the North Department, 2017 for the global French population sample). Medicinal
23 products were identified by ATC class (Anatomical Therapeutic Chemical Classification System).
24 These numbers were calculated for each 5 year-age classes from 35 years old and each gender,
25 estimating the expected number of individuals in each class of age and gender (12) that were
26 prescribed ACEI, ARB and other antihypertensive drugs.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

The third one was the 2005–2007 MONA LISA cross-sectional survey of cardiovascular risk factors and nutrition carried out by the French Lille MONICA (monitoring of trends and determinants in cardiovascular disease) centre (13). This sample included 1,584 men and women aged 35–75 living in the Lille urban area, randomly selected from the electoral rolls. Detailed information on anthropometric, demographic and health data including treatments coded according to the ATC class were available. As for the two previous reference samples the numbers of individuals that had an ACEI, an ARB or any antihypertensive drug were calculated for each 5 year-age classes and each gender. In addition, a third stratification level was considered based on the Body Mass Index (BMI) coded in three classes as normal (18.5-25 kg/m²), overweight (25-30 kg/m²) and obese (≥30 kg/m²).

Statistical analysis

As a continuous variable, age was expressed as mean and standard deviation. Categorical data were summarised as counts and percentages. For the 95% confidence interval of proportion where the numbers were less than 5, fluctuation interval was calculated according to binomial law. For each of the four groups of severity a standardised prevalence ratio of consumption of each type of drug and a 95% confidence interval were calculated (14). Firstly, an observed number of prescription was calculated; secondly, the number of consumption estimated was calculated by applying the stratum-specific prevalence rates by 5 year age classes and gender obtained from two reference populations : the exhaustive population of the North of France (R1) and the representative sample of the French population (R2). A third type of standardised prevalence ratio of consumption were calculated for the ICU sample stratified on age classes, gender and BMI classes obtained from the MONA LISA cross-sectional survey . We calculated the necessary number of individuals to include in our study based on comparison of two binomial proportions. Statistical analyses were performed using R software (version 3.3.1) (RCore Team, 2016) and Epitools package (version 0.5-7).

Results

The total number of patients aged over 35 years suspected of or diagnosed with COVID-19 in the CHU Lille during the study period was 288 (Table 1). Among these, 62% were male and almost 70% in ICU. COVID-19 was confirmed in 187 patients. An anti-hypertensive treatment was prescribed in 19.7% of the patients referred to the outpatient clinic, while for patients hospitalised in ICU who were all COVID-19 positive, this percentage was over fifty. The prevalence of diabetes almost doubled between patients in outpatient clinic and hospitalised patients and still doubled between hospitalised patients and patients transferred in ICU. No difference in respiratory disease prevalence could be observed, while chronic kidney and cardiovascular diseases prevalences were higher in hospitalised and ICU patients. The distribution of these comorbidities tends to highlight a different severity of the disease among the three groups. The emergency calls group of suspected COVID-19 individuals was very similar to the North of France population group and to the French National sample in term of gender distribution and prevalence of anti-hypertensive treatments.

In table 2, we calculated the prevalence of consumption of any anti-hypertensive drug, ACEI and ARB in the different groups of patients. More than half of the most severe cases, in hospital and ICU, were treated with antihypertensive drugs, this observation being consistent with the higher mean ages of these two samples and with hypertension as a potential prognostic factor for the COVID-19 severity. In a first attempt to estimate a possible additional increased risk of infection by SARS-CoV2 among patients treated by anti-hypertensive drugs, especially those treated with ACEI or ARB, we compared the proportion of ACEI and ARB use among all classes of anti-hypertensive treatments. These proportions were highly comparable (between 70 and 74%) between the two population reference samples and the one of the hospitalised and ICU patients, suggesting no clinically significant increase in ACEI and ARB prescription at entry, even for the more severe cases.

When the reference population was the North of France population (Table 3), there was no significant difference between the standardised prevalence ratio (SPR) of the ACEI and ARB drugs in the COVID-19 positive patients. This absence of significant difference between the SPR of the ACEI

1 and ARB drugs was also observed for all the four groups, except for patients in ICU where SPR for
 2 ARB drugs was significantly higher (1.56 [1.02-2.39]). This difference was in line with the other SPRs
 3 estimated with France National sample (1.63 [1.07-2.51]). To exclude a potential confounding factor
 4 in this increase in the use of ARB in ICU, conversely to what is observed in COVID-19 positive patients
 5 in outpatient clinic and hospitalisation, we stratified the ICU population according to obesity, a major
 6 prognostic factor of severity (15). In table 4, we calculated the SPR of the ACEI, ARB and other
 7 antihypertensive drugs using the MONA LISA Lille study, a representative sample of the Lille urban
 8 area as the reference group. We stratified the ICU population in three categories of BMI. In this
 9 severe prognostic sample, 43% of the patients were obese and 43% overweight. In ICU, the SPR
 10 increase in ARB, although not significant due to a lack of statistical power, was limited to the obese
 11 group. This suggested that the higher consumption of this drug may be related to the importance of
 12 the co-morbidity associated with obesity and not to a potential deleterious interaction with SARS-
 13 CoV2 infection. Accordingly, the median BMI in the obese patients in ICU (36.9) was higher than the
 14 one in the obese subjects of the MONA LISA Lille study (33.0).

15

16 Discussion

17 In this monocentric study, the standardised prevalence ratios of consumption of ACEI and ARB drugs
 18 were similar to the regular consumption of this drug in the North of France population and more
 19 generally, in a representative sample of France. In addition, these standardised prevalence ratios did
 20 not differ as the severity of the COVID-19 patients increased. However a statistically significant
 21 increase in the SPR of ARB drugs was observed in ICU only. After stratification on BMI, this increase
 22 of prescription was only observed in the obese patient group. This suggested a specific anti-
 23 hypertensive excess prescription of ARB in obese patients associated to a higher frequency of
 24 comorbidities, as hypertension and diabetes, and a highly deleterious prognostic for SARS-CoV2
 25 infection in this subgroup of patients.

1 We defined four groups of suspected and confirmed COVID-19 cases with an increasing severity of
 2 their clinical form. If a deleterious relationship between the use of ACEI or ARB had existed, we
 3 would have expected an enrichment of patients consuming these drugs in severe cases. One limit of
 4 our study was the size of the COVID-19 positive sample. However, at least a doubling of the
 5 proportion of treatments could justify a strong clinical reason to eventually change the regular anti-
 6 hypertensive treatment use. The number of patients needed to detect a doubling of the prescription
 7 of ARB or ACEI (10% in the North of France reference sample) was 122 for $\alpha = 5\%$ (2-tails) and $\beta =$
 8 10%. When we grouped all the COVID-19 positive cases (187 cases), we did not detect any significant
 9 difference of prescription of ACEI or ARB.

10 When we estimated the standardised prevalence ratio in each of the groups according to the
 11 increasing severity, we observed a significant difference in the ICU patients compared to the two
 12 reference population samples, 21 patients treated with ARB were observed versus 13.5 and 12.9
 13 expected, whereas these two numbers were similar among ACEI prescription. This could have been
 14 consistent with some basic evidences suggesting that the administration of ARB increased the level
 15 of cardiac ACE2 mRNA and activity while ACEI increased ACE2 mRNA levels only (16), ARB increasing
 16 the number of molecular gates for the SARS-CoV2. To better decipher this significant association, we
 17 explored in the ICU patients some of the risk factors of severity known to be associated with COVID-
 18 19. In particular, hypertension, estimated by the prevalence of use of anti-hypertensive drugs, had a
 19 frequency of 52% not different from the one observed in hospitalised patients (53%) where the use
 20 of ARB was not different from the one of the reference population samples ($SPR1 = 0.79 [0.40-1.59]$;
 21 $SPR2 = 0.81 [0.41-1.63]$). In these conditions, we could consider that this increase was not related to
 22 hypertension. Conversely, the frequency of diabetes was different between the different COVID-19
 23 positive groups : 15% for the hospitalised patients and 26% for ICU patients. This prompted us to
 24 stratify our population sample in ICU according to a major risk factor associated with diabetes,
 25 increased cardiovascular risk and severe acute respiratory syndrome needing mechanical ventilation,
 26 i.e. obesity (15). Indeed, 43.2% of the ICU patients were obese and 43.2% were overweight. We

1 stratified our samples according to age, gender and BMI in three classes and standardised our
2 prevalence ratio of consumption with the expected number of subjects from of a random sample of
3 the population were the ICU patients were located. The number of obese patients with ARB was 13
4 and the expected number was 9.4, while for overweight and normal patients these numbers were
5 strictly identical. This result suggested that the doubling of the prescription of ARB in ICU patients
6 was explained by the higher frequency of obese patients doubled in ICU (43.2%) compared to the
7 one of the surrounding population (22.4%) (13). Obesity as a major prognosis risk factor for COVID-
8 19 deserves further attention. Our European results are complementary to a retrospective study
9 among hospitalised COVID-19 patients in China with hypertension where the inpatient use of
10 ACEI/ARB was associated with a lower risk of all-cause mortality compared with ACEI/ARB non-users
11 (17). In this study, the prescribing habits for hypertension were very different from the ones of the
12 European populations. Indeed only 17% (188/1128) of their hypertensive patients were treated with
13 ACEI/ARB while this figure was between 70 and 74% in our population samples. Therefore our results
14 reinforced the interest to maintain ARB/ACEI treatments for COVID-19 positive patients in a
15 European context of drug prescription. In addition to this Chinese sample, our study, taking into
16 account non-hospitalised patients, supported the hypothesis that ACEI/ARB may not increase the
17 probability of infection by SARS-CoV2 in the general population people.

18 In conclusion, our results suggest that the risks of infection by SARS-CoV2 and of an increased
19 severity in patients suspected of or diagnosed with COVID-19 were not associated with an excess in
20 consumption of ACEI and ARB (Summarising figure). Thus, based on the basic, experimental and
21 clinical evidences of the high organ protective effects of ACEI and ARB, and despite all the theoretical
22 deleterious hypotheses induced by the knowledge that the penetration gate of the SARS-CoV2 is the
23 ACE2, our results strongly support the recommendation that RAAS inhibitors should be continued.
24 Our results reinforce the position of several scientific societies (18,19). The results of our clinical
25 epidemiology approach of the key question of the RAAS inhibitor in COVID-19 patients should be
26 confirmed in other sample populations and countries around the world.

1 Fundings

2 This work was supported by the Centre Hospitalier Universitaire de Lille (CHU Lille), the Lille
3 University, the Institut National de la Santé et de la Recherche Médicale (Inserm) and the Institut
4 Pasteur de Lille.

6 Acknowledgments

7 We thanks all the persons composing the Lille COVID-19 study group who have made substantial
8 contributions to this manuscript (e.g. data acquisition (DA), analysis (A), or writing / editing
9 assistance (E)) and helped to finalized this study in the shortest delays : Loic André¹ (DA), Ady Assaf²
10 (DA), Edgar Bakhache¹ (DA), Marcellin Bellonet³ (DA), Nordine Benameur⁴ (DA), Antoine Bidault⁴
11 (DA), Brigitte Bonneau⁵ (DA), Amélie Cerf⁶ (DA), Marie-Charlotte Chopin² (DA), Brigitte Courtois³ (DA),
12 Maureen Decroo³ (DA), Claire Delcourte⁶ (DA), Anne-Laure Demarty³ (DA), Dominique Deplanque³
13 (DA), Aurélie Dozier² (DA), Marie-Pierre Dumont⁷ (DA), Emmanuel Faure² (DA), Raphael Favory^{6,7}
14 (DA), Claude Gady-Cherrier⁸ (DA and A), Corinne Gower^{5,9} (DA), Nathalie Guillon⁵ (DA), Mercé
15 Jourdain⁶ (DA), Marine Letrionnaire⁸ (DA and A), David Messing⁸ (DA and A), Saad Nseir⁶ (DA), Hélène
16 Pennel⁵ (DA), Anne Pétilon⁵ (DA), Mohammad-Ryad Pokeerbux¹ (DA), Sébastien Préau^{6,7} (DA),
17 Armand Rémy⁴ (DA), Renan Targhetta³ (DA), Sébastien Sanges¹ (DA), Sarah Stabler² (DA), Sophie
18 Tallon³ (DA), Corinne Vantourout⁵ (DA), Fanny Vuotto² (DA). (1. CHU Lille, Internal Medicine
19 Department, F-59000, Lille, France ; 2. CHU Lille, Department of Infectious Diseases, F-59000, Lille,
20 France ; 3. CHU Lille, Department of Research and Innovation, F-59000, Lille, France ; 4. CHU Lille,
21 SAMU 59 and Emergency Department, F-59000, Lille, France ; 5. CHU Lille, Department of Public
22 Health, Epidemiology, Medical Economy and Prevention, F-59000, Lille, France ; 6. CHU Lille,
23 Department of Intensive Care, F-59000, Lille, France ; 7. Univ. Lille, Inserm, CHU Lille, Institut Pasteur
24 de Lille, U1167 - RID-AGE - Risk factors and molecular determinants of aging-related diseases, F-
25 59000, Lille, France ; 8. DRSM Hauts de France, F-59009, Villeneuve d'Ascq, France ; 9. Univ. Lille,
26 Inserm, CHU Lille, U1286 – Infinite- Institute for Translational Research in Inflammation, F-59000,

1 Lille, France). We are grateful to the medical students and the staff of the emergency call platform of
2 the CHU Lille, to all the clinicians, the nurses and the non-medical staff, the Lille logistic departments
3 and administrations of the CHU Lille involved in the COVID-19 care without whom this work would
4 not have been possible.

5

6 **Conflict of interest**

7 None declared. Philippe AMOUYEL reports, outside the submitted work, personal fees from
8 Fondation Alzheimer and personal fees and other from Genoscreen.

9

10

References

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19.. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020 Feb 28 ; doi: 10.1056/NEJMoa2002032. [Epub ahead of print]
2. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020 Mar 26 ; 368:m1091. doi: 10.1136/bmj.m1091.
3. Zhao X, Zhang B, Li P, Ma C, Gu J, Hou P, Guo Z, Wu H, Bai Y. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv 2020 ; doi: <https://doi.org/10.1101/2020.03.17.20037572>
4. Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, Lavandero S. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol 2020;17:116-29.
5. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020 Mar 30. ; doi: 10.1056/NEJMs2005760. [Epub ahead of print]
6. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020 Mar 4 ; pii: S0092-8674(20)30229-4. doi: 10.1016/j.cell.2020.02.052. [Epub ahead of print]

- 1 7. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B,
2 Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related
3 carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ Res* 2000 ; 87:E1-9.
- 4 8. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its
5 effect on the prognosis of COVID-19. *J Med Virol.*2020 Mar 27; doi: 10.1002/jmv.25785. [Epub ahead
6 of print]
- 7 9. Sparks MA, South A, Welling P, Luther JM, Cohen J, Byrd JB, Burrell LM, Batlle D, Tomlinson L,
8 Bhalla V, Rheault MN, Soler MJ, Swaminathan S, Hiremath S. Sound Science before Quick Judgement
9 Regarding RAS Blockade in COVID-19. *Clin J Am Soc Nephrol* 2020 Mar 27 ; pii: CJN.03530320. doi:
10 10.2215/CJN.03530320. [Epub ahead of print]
- 11 10. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol.* 2020
12 Mar 5 ; doi: 10.1038/s41569-020-0360-5. [Epub ahead of print]
- 13 11. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance
14 information system and the permanent beneficiaries sample. *Rev Epidemiol Sante Publique* 2010
15 ;58:286-90.
- 16 12. Tuppin P, Ricci-Renaud P, de Peretti C, Fagot-Campagna A, Gastaldi-Menager C, Danchin N, Alla F,
17 Allemand H. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in
18 2010. *Arch Cardiovasc Dis* 2013;106:274-86.
- 19 13. Goumidi L, Cottel D, Dallongeville J, Amouyel P, Meirhaeghe A. Effects of established BMI-
20 associated loci on obesity-related traits in a French representative population sample. *BMC Genet.*
21 2014 ;15:62. doi: 10.1186/1471-2156-15-62.
- 22 14. Greenland S and Rothman KJ. Introduction to categorical statistics. In : Greenland S and Rothman
23 KJ Eds, *Modern Epidemiology*, 2nd Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 1998 :
24 231-252.

- 1 15. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, Labreuche J, Mathieu D,
2 Pattou F, Jourdain M, Lille Intensive Care COVID-19 and Obesity study group. High prevalence of
3 obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive
4 mechanical ventilation. Obesity (Silver Spring) 2020 Apr 9. doi: 10.1002/oby.22831. [Epub ahead of
5 print]
- 6 16. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE.
7 Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac
8 angiotensin-converting enzyme 2. Circulation 2005;111:2605-10.
- 9 17. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng
10 X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai
11 H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH,
12 Huang X, Yuan Y, Rohit L, Liu PP, Li H. Association of Inpatient Use of Angiotensin Converting Enzyme
13 Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension
14 Hospitalized With COVID-19. Circ Res. 2020 Apr 17. doi: 10.1161/CIRCRESAHA.120.317134. [Epub
15 ahead of print]
- 16 18. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin
17 Receptor Blockers. Available at [https://www.escardio.org/Councils/Council-on-Hypertension-](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang)
18 [/CHT\)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang).
19 (April 21st 2020)
- 20 19. A statement from the International Society of Hypertension on COVID-19. Available at :
21 [https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-](https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/)
22 [COVID-19/ \(April 21st 2020\)](https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/)

23

1 **Take-home figure legend** : No excess of consumption of ACEI and ARB as severity increased in
2 patients with COVID-19 suggesting RAAS inhibitors should be continued. No more excess of
3 consumption of ARB in ICU when stratified on Body Mass Index. (ACEI = Angiotensin Converting
4 Enzyme Inhibitor; ARB = AT1 receptor blocker ; ICU = Intensive Care Unit.)

5

6 **One-Sentence Summary:** These results strongly support the recommendation to continue
7 angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in COVID-19 positive
8 patients.

9

1 Table 1. Description of the population samples

	Outpatient clinic CHU Lille	Hosp. Patients CHU Lille	ICU CHU Lille	Emergency calls	North of France population (R1)	France National sample (R2)
n	139	61	88	804	1,569,968	414,046
men	82	36	61	375	700,097	198,162
n, (%)	(59%)	(59%)	(69%)	(47%)	(45%)	(48%)
Age mean, (sd)	49.7 (11.3)	58.2 (20.2)	60.7 (14)	52.7 (13.3)	57.3 (18.8)	58.3 (15.2)
HTA ttt n, (%)	27 (19%)	32 (53%)	46 (52%)	203 (25%)	468,602 (30%)	119,393 (29%)
COVID+ n, (%)	38 (27%)	61 (100%)	88 (100%)	NA	NA	NA
Diabetes n, (%)	8 (6%)	9 (15%)	23 (26%)	NA	NA	NA
Respiratory diseases n, (%)	16 (12%)	5 (8%)	10 (11%)	NA	NA	NA
Kidney diseases n, (%)	1 (1%)	4 (7%)	4 (5%)	NA	NA	NA

Cardiovasc.	16	14	18	NA	NA	NA
Diseases	(12%)	(23%)	(21%)			
n, (%)						

1

2

1 **Table 2. Distribution of anti-hypertensive treatments**

2

	N	Any anti HTA drug n (%)	ACEI n (%)	ARB n (%)	ACEI or ARB / Any anti HTA drug %
Outpatient clinic COVID +	38	7 (18%)	4 (11%)	2 (5%)	86 [57-100]*
Outpatient clinic COVID -	101	20 (20%)	8 (8%)	9 (9%)	85 [70-100]*
Hospitalised COVID+	61	32 (53%)	14 (23%)	8 (13%)	69 [53-85]
ICU COVID +	88	46 (52%)	13 (15%)	21 (24%)	74 [61-87]
Emergency calls	804	203 (25%)	70 (9%)	82 (10%)	74 ⁺ [68-80]
North of France population (R1)	1,569,968	468,602 (30%)	163,526 (10%)	174,204 (11%)	71 ⁺ [70-71]
France National sample (R2)	414,046	119,393 (29%)	38,760 (9%)	46,931 (11%)	70 ⁺ [69-70]

3

4

5 * Fluctuation interval binomial law

6 ⁺ Individuals with association of ACEI and ARB were counted once only

1

2 **Table 3. Standardised prevalence ratio of consumption of anti-hypertensive drugs**

3

4

5

	Treatment	Obs.	Exp. R1	SPR1 [95%CI]	Exp. R2	SPR2 [95%CI]
All patients						
	ACEI	31	26.4	1.17 [0.83-1.67]	22.1	1.40 [0.99-1.99]
COVID +	ARB	31	26.4	1.17 [0.83-1.67]	25.4	1.22 [0.86-1.73]
	Other drugs	23	18.6	1.23 [0.82-1.86]	17.7	1.30 [0.86-1.95]
	ACEI	78	76.1	1.03 [0.82-1.28]	61.7	1.26 [1.01-1.58]
COVID -	ARB	91	76.5	1.19 [0.97-1.46]	72.2	1.26 [1.03-1.55]
	Other drugs	56	62.5	0.90 [0.69-1.17]	57.2	0.98 [0.75-1.27]
Emerg. calls						
	ACEI	70	68.8	1.02 [0.81-1.29]	55.9	1.25 [0.99-1.58]
	ARB	82	69.7	1.18 [0.95-1.46]	65.9	1.24 [1.00-1.55]
	Other drugs	53	57.0	0.93 [0.71-1.22]	52.4	1.01 [0.77-1.32]

Outpatients						
	ACEI	4	3.2	1.24 [0.47-3.31]	2.5	1.57 [0.59-4.19]
COVID +	ARB	2	2.9	0.70 [0.18-2.80]	2.7	0.74 [0.18-2.95]
	Other drugs	1	2.3	0.43 [0.06-3.07]	2.0	0.50 [0.07-3.53]
	ACEI	8	7.3	1.10 [0.55-2.19]	5.8	1.39 [0.69-2.78]
COVID -	ARB	9	6.8	1.32 [0.69-2.54]	6.3	1.42 [0.74-2.73]
	Other drugs	3	5.5	0.55 [0.18-1.70]	4.8	0.62 [0.20-1.93]
Hospitalised						
	ACEI	14	9.5	1.47 [0.87-2.49]	8.1	1.72 [1.02-2.90]
COVID +	ARB	8	10.1	0.79 [0.40-1.59]	9.8	0.81 [0.41-1.63]
	Other drugs	10	7.1	1.41 [0.76-2.63]	6.9	1.44 [0.78-2.68]
ICU						
	ACEI	13	13.7	0.95 [0.55-1.64]	11.4	1.14 [0.66-1.96]
COVID +	ARB	21	13.5	1.56 [1.02-2.39]	12.9	1.63 [1.07-2.51]
	Other drugs	12	9.3	1.30 [0.74-2.28]	8.8	1.37 [0.78-2.41]

1

2 R1 : North of France population reference, R2 : France National sample reference

1 **Table 4. Distribution of anti-hypertensive drugs in ICU according to BMI**

2

		ACEI			ARB			Other drugs		
	n	Obs.	Exp.	SPR [95%CI]	Obs.	Exp.	SPR [95%CI]	Obs.	Exp.	SPR [95%CI]
All	88	13	10.7	1.22 [0.71-2.09]	21	15.5	1.36 [0.88-2.08]	12	6.7	1.79 [1.02-3.15]
Normal	12	1	1.2	0.86 [0.12-6.09]	1	0.9	1.11 [0.16-7.91]	4	0.7	5.58 [2.09-14.86]
Overweight	38	5	5.4	0.93 [0.39-2.22]	7	7.0	1 [0.47-2.09]	3	2.6	1.14 [0.37-3.53]
Obese	38	7	4.8	1.47 [0.70-3.08]	13	9.4	1.38 [0.80-2.38]	5	3.8	1.32 [0.55-3.16]

3

4 Data calculated with the MONA LISA Lille study as the reference population